Chromadex Corp.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Other
ICLRICON plc -1.33%236.772.8%$120.94m
ARGXargenx SE -0.85%379.350.0%$89.03m
VRXValeant Pharmaceuticals International, Inc. -3.87%5.7114.1%$33.60m
RVMDRevolution Medicines, Inc. -7.48%22.390.0%$27.51m
ENVBEnveric Biosciences, Inc. 4.53%7.040.0%$4.85m
USNAUSANA Health Sciences, Inc. -0.39%71.914.2%$4.51m
ANIKAnika Therapeutics, Inc. 0.74%23.039.7%$1.75m
CLVRClever Leaves Holdings, Inc. -1.13%0.970.0%$1.53m
BGXXBright Green Corp. -3.66%1.190.0%$0.97m
CDTXCidara Therapeutics, Inc. -0.70%0.700.7%$0.62m
CDXCChromadex Corp. 0.54%1.652.7%$0.59m
FLGCFlora Growth Corp. 0.31%0.940.0%$0.56m
PMCBPharmaCyte Biotech, Inc. -0.64%2.810.0%$0.49m
IBIOiBio, Inc. -1.00%0.280.2%$0.47m
SMFLSmart for Life, Inc. -1.25%0.560.0%$0.41m

Company Profile

Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.